DMO: Study finds faricimab provides sustained retinal stability

Article

During a presentation at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Veeral Sheth presented research that found faricimab, a bispecific monoclonal antibody, provided sustained retinal stability in patients with diabetic macular oedema (DMO) compared with other retinal treatments.

DMO: Study finds faricimab provides sustained retinal stability

In a study, outlined at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Veeral Sheth and colleagues reported that faricimab, a bispecific monoclonal antibody, provided sustained retinal stability in patients with diabetic macular oedema (DMO) compared with other retinal treatments.

In preclinical studies, blocking angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF-A) reduced the vascular leakage/neovascularization, inflammation, and fibrosis.

In a phase 2 post hoc analyses, the investigators assessed, in the intention-to-treat population, the sustained retinal stability, defined as occurrence and less than 10% worsening of the central subfield to 325 microns or less to week 24. The inflammatory biomarker, intercellular adhesion molecule-1 (ICAM-1), levels also were assessed in a patient subset from baseline to week 28.

The investigators reported that more than 50% of patients achieved sustained retinal stability at weeks 8 and 16 with faricimab compared with week 20 with ranibizumab (Lucentis, Genentech). At week 28, the mean percentage of the ICAM-1 levels compared with baseline increased by 50% with ranibizumab and decreased by 56% and 42% in the 2 faricimab arms.

The investigators concluded that faricimab resulted in sustained retinal stability and ICAM-1 reduction compared with ranibizumab in the phase 2 study. In addition, in the phase 3 studies, faricimab showed greater anatomic improvement compared with aflibercept (Eyelea, Regeneron) and potential for improved durability due to vascular stability by Ang-2 inhibition.

Faricimab is the only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.

Related Content: Additional AAO content | Retina | Gene Therapy

Related Videos
A screenshot of Dr Filomena Ribeiro, president of the ESCRS
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
© 2024 MJH Life Sciences

All rights reserved.